Imagion Biosystems Ltd - Asset Resilience Ratio
Imagion Biosystems Ltd (IBX) has an Asset Resilience Ratio of 75.37% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IBX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2019)
This chart shows how Imagion Biosystems Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see IBX asset base.
Liquid Assets Composition Over Time
This chart breaks down Imagion Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read IBX liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$4.33 Million | 75.37% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$4.33 Million | 75.37% |
Asset Resilience Insights
- Very High Liquidity: Imagion Biosystems Ltd maintains exceptional liquid asset reserves at 75.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Imagion Biosystems Ltd Industry Peers by Asset Resilience Ratio
Compare Imagion Biosystems Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Imagion Biosystems Ltd (2016–2019)
The table below shows the annual Asset Resilience Ratio data for Imagion Biosystems Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 69.82% | AU$3.40 Million ≈ $2.41 Million |
AU$4.87 Million ≈ $3.45 Million |
-14.37pp |
| 2018-12-31 | 84.19% | AU$4.37 Million ≈ $3.09 Million |
AU$5.19 Million ≈ $3.67 Million |
-5.76pp |
| 2017-12-31 | 89.94% | AU$6.87 Million ≈ $4.86 Million |
AU$7.64 Million ≈ $5.41 Million |
+89.72pp |
| 2016-12-31 | 0.23% | AU$27.64K ≈ $19.56K |
AU$12.14 Million ≈ $8.59 Million |
-- |
About Imagion Biosystems Ltd
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing th… Read more